A Comparison of the Effectiveness and Safety of Glimepiride with Sitagliptin in Patients with Type 2 Diabetes Mellitus
Authors/Creators
- 1. Tutor, Department of Pharmacology, Nalanda Medical College, Patna, Bihar
- 2. Associate Professor, Department of Pharmacology, Nalanda Medical College, Patna, Bihar
Description
Background: One of the key reasons why treating people with diabetes mellitus (DM) and society at large is expensive. To contrast sitagliptin safety and efficiency with glimepiride in Type 2 DM patients who are also being treated with metformin as a background. Methods: From December 2021 to November 2022, this study was carried out at NMCH, Patna, Bihar. Eligible patients were randomly assigned to receive sitagliptin 100 mg and glimepiride 2 mg once daily as an add-on medication for 12 weeks. A pre-populated proforma was filled up with demographic data. All study participants/patients heard advice to keep up a healthy diet and exercise frequently. At week 0 and again at week 12, which is when the trial came to an end, all patients’ HbA1C, FBS, weight, Alanine Aminotransferase (ALT), serum urea, and serum creatinine measurements were obtained. The primary goal was to reach the target HbA1C upper normal level at the end of the study. Results: A total of 120 patients were enrolled in the experiment, with 60 in each group. There were 36 men and 24 women in group B, compared to 32 men and 28 women in group A. Group A utilising sitagliptin demonstrated a statistically significant decline in HbA1C and BMI when compared to the Glimepiride group. (p<0.05). The two groups’ reductions in FBS were comparable (p>0.05). Hypoglycemia, diarrhoea, and vomiting were the most frequent adverse reactions in both groups. There was no statistically significant difference in the frequency of occurrence between the two groups (p>0.05). Conclusion: The results of the current research show that sitagliptin, when taken in addition to metformin, improves glycemic control just as effectively as glimepiride and is well tolerated with no obvious side effects. Glimepiride fared worse than sitagliptin, which also had a decreased risk of hypoglycemia. In addition, it was well tolerated and caused weight loss when compared to glimepiride.
Abstract (English)
Background: One of the key reasons why treating people with diabetes mellitus (DM) and society at large is expensive. To contrast sitagliptin safety and efficiency with glimepiride in Type 2 DM patients who are also being treated with metformin as a background. Methods: From December 2021 to November 2022, this study was carried out at NMCH, Patna, Bihar. Eligible patients were randomly assigned to receive sitagliptin 100 mg and glimepiride 2 mg once daily as an add-on medication for 12 weeks. A pre-populated proforma was filled up with demographic data. All study participants/patients heard advice to keep up a healthy diet and exercise frequently. At week 0 and again at week 12, which is when the trial came to an end, all patients’ HbA1C, FBS, weight, Alanine Aminotransferase (ALT), serum urea, and serum creatinine measurements were obtained. The primary goal was to reach the target HbA1C upper normal level at the end of the study. Results: A total of 120 patients were enrolled in the experiment, with 60 in each group. There were 36 men and 24 women in group B, compared to 32 men and 28 women in group A. Group A utilising sitagliptin demonstrated a statistically significant decline in HbA1C and BMI when compared to the Glimepiride group. (p<0.05). The two groups’ reductions in FBS were comparable (p>0.05). Hypoglycemia, diarrhoea, and vomiting were the most frequent adverse reactions in both groups. There was no statistically significant difference in the frequency of occurrence between the two groups (p>0.05). Conclusion: The results of the current research show that sitagliptin, when taken in addition to metformin, improves glycemic control just as effectively as glimepiride and is well tolerated with no obvious side effects. Glimepiride fared worse than sitagliptin, which also had a decreased risk of hypoglycemia. In addition, it was well tolerated and caused weight loss when compared to glimepiride.
Files
IJPCR,Vol15,Issue4,Article189.pdf
Files
(359.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:21af19e4c22e41ad17d9c697f24769ba
|
359.3 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-03-30
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue4,Article189.pdf
- Development Status
- Active
References
- 1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-53. 2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–65. 3. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005–12. 4. Choy M, Lam S. Sitagliptin: a novel drug for the treatment of type 2 diabetes. Cardiol Rev 2007 ;15:264-71. 5. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287:360–72. 6. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, et al... Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin Pharm Therap 2005;78:675-88. 7. Drucker DJ, Nauck MA. GLP-1R agonists (incretinmimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes. Lancet 2006; 368:1696-1705. 8. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al... Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;49:2816–8. 9. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–71. 10. Arechavaleta R, Seck T, Chen Y, Krobot KJ, O'Neill EA, Duran L, et al... Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes ObesMetab 2011;13:160-8. 11. Charbonnelet B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43. 12. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes ObesMetab 2007;9:194-205.13. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979–87.